Avidity Biosciences Other Current Liabilities

As of the most recent data (June 2026), RNA shows a other current liabilities of $17M. That compares with $110M in the prior-year period — down 84.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RNA's other current liabilities is now $17M (was $110M) — a 84.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avidity Biosciences is outperforming or lagging.

Tracking RNA's other current liabilities over time shows whether Avidity Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $110M in the prior-year period — down 84.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Avidity Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $17M) with ownership activity and broader fundamentals.

Avidity Biosciences's other current liabilities is $17M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.